Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

MYB oncogene amplification in hereditary BRCA1 breast cancer

Author:
  • P Kauraniemi
  • Ingrid Hedenfalk
  • Karin Persson
  • D J Duggan
  • Minna Tanner
  • Oskar Johannsson
  • Håkan Olsson
  • J M Trent
  • Jorma Isola
  • Åke Borg
Publishing year: 2000
Language: English
Pages: 5323-5328
Publication/Series: Cancer Research
Volume: 60
Issue: 19
Document type: Journal article
Publisher: American Association for Cancer Research Inc.

Abstract english

Comparative genomic hybridization analysis has demonstrated that breast tumors from BRCA1 and BRCA2 germ-line mutation carriers contain a large number of chromosomal copy number gains and losses. A high regional copy number gain at 6q22-q24 was observed in one BRCA1 tumor, and fluorescence in situ hybridization analysis indicated a strong amplification of the MYB oncogene (15 copies of MYB compared with 1 copy of chromosome 6 centromere). Fluorescence in situ hybridization analysis revealed amplification of MYB in 5 (29%) of 17 BRCA1 breast tumors, whereas none of 8 BRCA2 tumors and 13 breast cancer cell lines, and only 2 of 100 sporadic breast tumors exhibited altered MYB copy numbers. Gene amplification resulted in mRNA overexpression as determined by Northern blot and cDNA microarray analysis, and protein overexpression by immunohistochemical staining. We conclude that MYB amplification is infrequent in sporadic breast cancer but common in breast tumors from BRCA1 mutation carriers, suggesting a role of this cell cycle regulator and transcription factor in the progression of some BRCA1 tumors. However, we cannot rule out the significance of other genes in the 6q22-q24 amplicon.

Keywords

  • Cancer and Oncology

Other

Published
  • ISSN: 1538-7445
Åke Borg
Åke Borg
E-mail: ake.borg [at] med.lu.se

Principal investigator

Oncology and Pathology, MV

+46 46 275 25 52

MV 404 C21B2

90

Project manager

Familial Breast Cancer

90

Professor

Oncology and Pathology, MV

MV 404 C21C2

90